Developing breakthrough treatments for fibrotic diseases


Pliant Therapeutics is an early-stage biotechnology company harnessing the therapeutic capabilities of integrin biology and TGF-β signaling to develop breakthrough treatments for fibrotic diseases. By leveraging its powerful product engine, Pliant’s mission is to prevent or even reverse fibrosis, restoring organ function. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression and fuel biomarker discovery for efficient clinical trial design.


Year Invested: 2016
Location: Redwood, Calif.
Visit: www.pliantrx.com

Recent News

September 26, 2017
Pliant Appoints Katerina Leftheris, Ph.D., as Vice President of Chemistry and John Curnutte, M.D., Ph.D. to the Board of Directors

January 5, 2017
Pliant Therapeutics Appoints Leading Academic Researcher and Industry Veteran Rik Derynck, Ph.D. As Scientific Founder

August 30, 2016
Pliant Therapeutics Appoints Suzanne Bruhn, Ph.D., to Board of Directors

Read More News

Associated Team Members

Perry Karsen
Venture Partner

Neil Exter
Partner

Craig Muir
Partner/Chief Technology Officer

Charles Homcy, M.D.
Partner